Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with ...

For decades, the central dogma of molecular biology—DNA makes RNA, RNA makes protein, protein makes phenotype—was the guiding framework for understanding inheritance and disease. This model explained ...

TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel ...

“Our analyses show that the historical [human Rhinovirus] A genome represents an extinct lineage closely related to HRV A19 ...

Suggested Citation: "1 Introduction." National Academies of Sciences, Engineering, and Medicine. 2024. Charting a Future for Sequencing RNA and Its Modifications: A New Era for Biology and Medicine.

Two separate laboratory breakthroughs have produced RNA molecules that can build copies of themselves or assemble functional structures without any help from proteins or DNA. These results offer the ...

From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as ...

While the central dogma of molecular biology outlines the linear flow of genetic information from DNA to RNA to proteins (black lines), glycomics introduces a “3rd code of life”—glycans—that operates ...

There are many molecules with therapeutic potential, but it can be a challenge to deliver them to the right places at the right times. RNA is one such molecule; the sequences for different proteins ...

Researchers at the MRC Laboratory of Molecular Biology in Cambridge have discovered a ribozyme that is shockingly small, yet ...